Your browser doesn't support javascript.
loading
A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.
Bristol, Jillian A; Djavadian, Reza; Albright, Emily R; Coleman, Carrie B; Ohashi, Makoto; Hayes, Mitchell; Romero-Masters, James C; Barlow, Elizabeth A; Farrell, Paul J; Rochford, Rosemary; Kalejta, Robert F; Johannsen, Eric C; Kenney, Shannon C.
Afiliación
  • Bristol JA; Department of Oncology in Wisconsin Institutes for Medical Research, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Djavadian R; Department of Oncology in Wisconsin Institutes for Medical Research, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Albright ER; Department of Molecular Virology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Coleman CB; Department of Immunology & Microbiology, University of Colorado School of Medicine, Denver, Colorado, United States of America.
  • Ohashi M; Department of Oncology in Wisconsin Institutes for Medical Research, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Hayes M; Department of Oncology in Wisconsin Institutes for Medical Research, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Romero-Masters JC; Department of Oncology in Wisconsin Institutes for Medical Research, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Barlow EA; Department of Pathology and Laboratory Medicine, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Farrell PJ; Department of Oncology in Wisconsin Institutes for Medical Research, McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
  • Rochford R; Molecular Virology, Department of Medicine, Imperial College London, London, United Kingdom.
  • Kalejta RF; Department of Immunology & Microbiology, University of Colorado School of Medicine, Denver, Colorado, United States of America.
  • Johannsen EC; Department of Immunology and Microbiology, University of Colorado, Aurora, Colorado United States of America.
  • Kenney SC; Department of Molecular Virology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
PLoS Pathog ; 14(7): e1007179, 2018 07.
Article en En | MEDLINE | ID: mdl-30052684
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Activación Viral / Transactivadores / Infecciones por Virus de Epstein-Barr Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Activación Viral / Transactivadores / Infecciones por Virus de Epstein-Barr Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos